# FDA proposes excluding three GLP-1 ingredients from the 503B bulks list

> FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding.

- Evidence object: `story:fda-glp1-503b-bulks-list-proposal:v1`
- Evidence domain: Regulatory
- Date in source: 2026-04-30
- Source checked: 2026-07-29
- Published by PeptideScanner: 2026-07-29
- Story landing page: https://peptidescanner.com/stories/fda-glp1-503b-bulks-list-proposal/
- JSON record: https://peptidescanner.com/evidence/v1/objects/fda-glp1-503b-bulks-list-proposal-v1.json
- Content SHA-256: `9b689aad44877573fc601e9620170f769a22bcec89482f4dd2c319e61c54c1f6`

## Claims and source pins

### Headline

FDA proposes excluding three GLP-1 ingredients from the 503B bulks list ([`fda-glp1-bulks-proposal-2026`](#source-fda-glp1-bulks-proposal-2026))

### Summary

FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding. ([`fda-glp1-bulks-proposal-2026`](#source-fda-glp1-bulks-proposal-2026))

### Paragraph 1

FDA announced a proposal concerning semaglutide, tirzepatide, and liraglutide and the 503B bulks list used by outsourcing facilities. ([`fda-glp1-bulks-proposal-2026`](#source-fda-glp1-bulks-proposal-2026))

### Paragraph 2

The agency action is a proposal, not a final rule or a statement that all compounding circumstances are identical. This update preserves that procedural distinction. ([`fda-glp1-bulks-proposal-2026`](#source-fda-glp1-bulks-proposal-2026))

## Sources

<a id="source-fda-glp1-bulks-proposal-2026"></a>
- **FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list) (`fda-glp1-bulks-proposal-2026`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "FDA proposes excluding three GLP-1 ingredients from the 503B bulks list." Version 1, published 2026-07-29. https://peptidescanner.com/evidence/v1/objects/fda-glp1-503b-bulks-list-proposal-v1.json SHA-256: 9b689aad44877573fc601e9620170f769a22bcec89482f4dd2c319e61c54c1f6.